

Robert Bourge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10548724/publications.pdf>

Version: 2024-02-01

11
papers

2,721
citations

933447

10
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

2021
citing authors

#	ARTICLE	IF	CITATIONS
1	Short-term Intravenous Milrinone for Acute Exacerbation of Chronic Heart Failure¹A Randomized Controlled Trial</sup>. JAMA - Journal of the American Medical Association, 2002, 287, 1541.	7.4	1,050
2	A RANDOMIZED ACTIVE-CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS¹. Transplantation, 1998, 66, 507-515.	1.0	545
3	BG9719 (CVT-124), an A₁ Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function Observed With Diuretic Therapy. Circulation, 2002, 105, 1348-1353.	1.6	348
4	Three-Year Results of a Randomized, Double-Blind, Controlled Trial of Mycophenolate Mofetil Versus Azathioprine in Cardiac Transplant Recipients. Journal of Heart and Lung Transplantation, 2005, 24, 517-525.	0.6	237
5	A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. American Heart Journal, 2011, 161, 329-337.e2.	2.7	170
6	Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: a multi-institutional study of preoperative weight-height indices. Journal of Heart and Lung Transplantation, 1999, 18, 750-763.	0.6	144
7	Subgroup Analysis of a Randomized Controlled Trial Evaluating the Safety and Efficacy of Cardiac Contractility Modulation in Advanced Heart Failure. Journal of Cardiac Failure, 2011, 17, 710-717.	1.7	91
8	Post-Operative Obesity and Cachexia Are Risk Factors for Morbidity and Mortality After Heart Transplant: Multi-Institutional Study of Post-Operative Weight Change. Journal of Heart and Lung Transplantation, 2005, 24, 1424-1430.	0.6	63
9	A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: Rationale, design, and baseline patient characteristics. American Heart Journal, 2008, 156, 641-648.e1.	2.7	36
10	Effects of Continuous Aortic Flow Augmentation in Patients With Exacerbation of Heart Failure Inadequately Responsive to Medical Therapy. Circulation, 2008, 118, 1241-1249.	1.6	32
11	Rationale, Design, and Methods for a Pivotal Randomized Clinical Trial of Continuous Aortic Flow Augmentation in Patients With Exacerbation of Heart Failure: The MOMENTUM Trial. Journal of Cardiac Failure, 2007, 13, 715-721.	1.7	5